Nordson Corp (ND1.MU)
Munich - Munich Delayed price. Currency in EUR
Add to watchlist
As of 08:26AM CEST. Market open.
| Previous close | 212.80 |
| Open | 216.20 |
| Bid | 216.40 x N/A |
| Ask | 218.20 x N/A |
| Day's range | 216.20 - 216.20 |
| 52-week range | 200.00 - 258.10 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 19 Aug 2024 - 23 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksNordson (NDSN) to Acquire Atrion & Boost Medical Offerings
Nordson (NDSN) announces to acquire Atrion. This will enable it to strengthen its medical offerings and boost its position in the infusion and cardiovascular therapies market.
Business WireNordson Corporation Announces Agreement to Acquire Atrion Corporation, a Market Leader in Medical Infusion and Cardiovascular Technologies
WESTLAKE, Ohio, May 28, 2024--Nordson Corporation (Nasdaq: NDSN) today announced that it has entered into a definitive agreement to acquire Atrion Corporation (Nasdaq: ATRI), a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions, for $460.00 per share in cash. This reflects a valuation of 15X Atrion’s 2024 full-year estimated EBITDA, inclusive of synergies Nordson expects to generate in the first two years of its ownership. The acquisition expands Nordson’s m
GuruFocus.comDecoding Nordson Corp (NDSN): A Strategic SWOT Insight
Insightful Analysis of Nordson Corp's Financial Health and Market Position
© 2024 Yahoo. All rights reserved.